Business
GT Biopharma Reports Third Quarter 2024 Financial Results
GTB-3650 TriKE® Phase 1 trial first patient dosed expected in Q4 2024; initial clinical data expected in Q2 2025GTB-5550 TriKE® IND submission for treatment
About this update from Gt Biopharma, Inc.
[{"type":"text","content":"GTB-3650 TriKE® Phase 1 trial first patient dosed expected in Q4 2024; initial clinical data expected in Q2 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in 1H 2025GTB-5550 Phase 1 dose escalation basket trial initiation expected in 2025 evaluating multiple solid tumor types, including prostate, breast, head and neck, ovarian, lung, liver, and GIGTB-7550 TriKE® targets CD19 and is in preclinical development for the treatment of Lupus and other autoimmune indicationsCash of approximately $6.5 million as of September 30, 2024, anticipated to be sufficient to fund operations into Q2 2025 SAN FRANCISCO, CALIFORNIA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced third quarter 2024 financial results for the period ended September 30, 2024. “We are pleased to be progressing towards dosing the first patient in our Phase 1 trial evaluating GTB-3650 in cancer patients in the fourth quarter of this year. This dose escalation study will evaluate GTB-3650 in 12 patients (six cohorts) with relapsed or refractory (r/r) CD33 expressing hematologic malignancies, including refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). We believe that NK cell engagers, like GTB-3650, have the potential to offer patients with a safer alternative to current treatments, like CAR-T therapy”, said Michael Breen, Executive Chairman and interim Chief Executive Office of GT Biopharma. This past October, the company held a virtual KOL event featuring Jeffrey Miller, MD1 and Mark Juckett, MD from the University of Minnesota Medical School2 who spoke to the value of NK cells within the broader therapeutic landscape as well as the potential for GT Biopharma’s NK cell engager pipeline, and specifically GTB-7550 which targets CD19 for autoimmune indications. “As a company, we are especially excited to continue exploring opportunities where our TriKE platform technology may have therapeutic utility, especially for autoimmune indications and in combination with NK cell therapies”, said Michael Breen. “In this rapidly emerging field, combination approaches may offer us the oppor...